Analyst Ratings For bluebird bio Inc (NASDAQ:BLUE)
Today, bluebird bio Inc (NASDAQ:BLUE) stock was downgraded by Goldman Sachs Group from Conviction-Buy to Buy.
There are 14 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on bluebird bio Inc (NASDAQ:BLUE) is Hold with a consensus target price of $212.05 per share, a potential 49.44% upside.
Some recent analyst ratings include
- 9/21/2018-bluebird bio Inc (NASDAQ:BLUE) gets downgraded to Buy by Goldman Sachs Group
- 9/17/2018-bluebird bio Inc (NASDAQ:BLUE) has coverage initiated with a Neutral rating
- 9/5/2018-bluebird bio Inc (NASDAQ:BLUE) had its Buy rating reiterated by William Blair
- 8/6/2018-bluebird bio Inc (NASDAQ:BLUE) had its Hold rating reiterated by Maxim Group
- 8/6/2018-bluebird bio Inc (NASDAQ:BLUE) had its Buy rating reiterated by Cowen
- 8/3/2018-bluebird bio Inc (NASDAQ:BLUE) had its Buy rating reiterated by SunTrust Banks with a $223.00 price target
Recent Insider Trading Activity For bluebird bio Inc (NASDAQ:BLUE)
bluebird bio Inc (NASDAQ:BLUE) has insider ownership of 3.00% and institutional ownership of 98.45%.
- On 9/10/2018 James Mandell, Director, sold 1,000 with an average share price of $150.77 per share and the total transaction amounting to $150,770.00.
- On 9/10/2018 Jeffrey T Walsh, Insider, sold 1,500 with an average share price of $150.16 per share and the total transaction amounting to $225,240.00.
- On 9/4/2018 David Davidson, Insider, sold 7,000 with an average share price of $166.64 per share and the total transaction amounting to $1,166,480.00.
- On 8/30/2018 Jeffrey T Walsh, Insider, sold 20,000 with an average share price of $175.40 per share and the total transaction amounting to $3,508,000.00.
- On 8/20/2018 Alison Cecily Finger, Insider, sold 259 with an average share price of $158.07 per share and the total transaction amounting to $40,940.13.
- On 8/10/2018 Jeffrey T Walsh, Insider, sold 1,500 with an average share price of $156.93 per share and the total transaction amounting to $235,395.00.
- On 8/6/2018 Philip D Gregory, Insider, sold 1,800 with an average share price of $156.61 per share and the total transaction amounting to $281,898.00.
About bluebird bio Inc (NASDAQ:BLUE)
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy; and Gritstone Oncology, Inc. to research, develop, and commercialize products for the treatment of cancer using cell therapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Recent Trading Activity for bluebird bio Inc (NASDAQ:BLUE)
Shares of bluebird bio Inc closed the previous trading session at 141,90 +0,60 0,42 % with 139.6 shares trading hands.
